These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 19883301

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 4. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
    Diehl V, Engert A.
    Nat Clin Pract Oncol; 2006 May 01; 3(5):227. PubMed ID: 16682982
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.
    Cavalieri E, Matturro A, Annechini G, De Angelis F, Frattarelli N, Gentilini F, Grapulin L, Sacco M, Torelli F, Vignetti M, Mandelli F, Foà R, Pulsoni A.
    Leuk Lymphoma; 2009 Nov 01; 50(11):1803-8. PubMed ID: 19860621
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M.
    J Clin Oncol; 1998 Dec 01; 16(12):3810-21. PubMed ID: 9850026
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
    Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein M, Kozak T.
    Leuk Lymphoma; 2012 Jan 01; 53(1):64-70. PubMed ID: 21740300
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
    Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P.
    Lancet Oncol; 2017 Dec 01; 18(12):1680-1687. PubMed ID: 29133014
    [Abstract] [Full Text] [Related]

  • 12. Chemotherapy: Advanced Hodgkin lymphoma--balancing toxicity and cure.
    Lim SH, Johnson PW.
    Nat Rev Clin Oncol; 2011 Sep 06; 8(11):634-6. PubMed ID: 21894205
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
    Belada D, Štěpánková P, Sýkorová A, Žák P, Smolej L.
    Leuk Lymphoma; 2015 Jul 06; 56(7):2013-8. PubMed ID: 25330440
    [Abstract] [Full Text] [Related]

  • 17. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M, German Hodgkin's Lymphoma Study Group.
    N Engl J Med; 2003 Jun 12; 348(24):2386-95. PubMed ID: 12802024
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Early treatment intensification with escalated BEACOPP in patients with Hodgkins lymphoma not responding to ABVD therapy.
    Danielewicz I, Małkowski B, Zaucha R, Zalewska M, Leśniewski-Kmak K, Zaucha JM.
    Acta Oncol; 2014 Feb 12; 53(2):286-8. PubMed ID: 24304391
    [No Abstract] [Full Text] [Related]

  • 20. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M.
    J Clin Oncol; 2009 Sep 20; 27(27):4548-54. PubMed ID: 19704068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.